A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL · Diffuse Large B-Cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 290 (planned)
- Started
- Jan 14, 2022
- Main results expected
- Sep 24, 2027
- Fully finished
- Sep 24, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1
Measured over: Up to ~6 weeks
Number of participants who experienced an adverse event (AE)
Measured over: Up to ~68 months
Number of participants who discontinued study treatment due to an AE
Measured over: Up to ~68 months
Overall survival (OS)
Measured over: Up to ~35 months
Progression-free survival (PFS)
Measured over: Up to ~35 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05139017 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC